The correlation between birth weight and insulin-like growth factor-binding protein-1 (IGFBP-1), kisspeptin-1 (KISS-1), and three-dimensional fetal volume.
Kimyon Comert. Gunsu G; Esin. Sertac S; Caglar. Gamze Sinem GS; Yirci. Bulent B; Ozdemir. Sedat S; Demirtas. Selda S; Kandemir. Omer O
Key Findings
- First‑trimester IGFBP‑1 levels were lower in mothers who later gave birth to large‑for‑gestational‑age (LGA) babies.
- Both low and high IGFBP‑1 levels were independently associated with small‑for‑gestational‑age (SGA) and LGA outcomes.
- KISS‑1 levels did not correlate with birth weight, fetal crown‑rump length, or three‑dimensional fetal volume.
Practical Outcomes
- For biohackers, this research suggests IGFBP‑1 might be a more promising early‑pregnancy biomarker for fetal growth than kisspeptin, but it offers no actionable protocol for using kisspeptin‑10 to improve metabolic or longevity outcomes. Measuring IGFBP‑1 could inform pregnancy monitoring, yet there’s no evidence to support supplementing kisspeptin for health benefits based on this study.
Summary
A study of 142 pregnant women found that the level of a protein called IGFBP‑1 in the mother's blood during the first trimester can hint at whether the baby will be unusually small or large at birth, while the hormone kisspeptin‑1 (KISS‑1) showed no useful link to baby size or early fetal growth.
Abstract
This study aimed to determine the relationship between birth weight, and maternal serum insulin-like growth factor-binding protein-1 (IGFBP-1) and kisspeptin-1 (KISS-1) levels, and first-trimester fetal volume (FV) based on three-dimensional ultrasonography. The study included 142 pregnant women at gestational week 11°-13<sup>6</sup>. All fetuses were imaged ultrasonographically by the same physician. Maternal blood samples were collected at the time of ultrasonographic evaluation and analyzed for IGFBP-1 and KISS-1 levels via enzyme-linked immunosorbent assay (ELISA). Maternal and neonatal weights were recorded at birth. Birth weight ≤10th and the >90th percentiles was defined as small and large for gestational age (SGA and LGA), respectively. Median crown-rump length (CRL), FV, and maternal serum IGFBP-1 and KISS-1 levels were 58.2 mm (35.3-79.2 mm), 16.3 cm<sup>3</sup> (3.8-34.4 cm<sup>3</sup>), 68.1 ng mL<sup>-1</sup> (3.8-377.9 mL<sup>-1</sup>), and 99.7 ng L<sup>-1</sup> (42.1-965.3 ng L<sup>-1</sup>), respectively. First-trimester IGFBP-1 levels were significantly lower in the mothers with LGA neonates (p < .05). There was a significant positive correlation between CRL and FV, and between the IGFBP-1 and KISS-1 levels. IGFBP-1 levels and maternal weight at delivery were negatively correlated with neonatal birth weight. There was no correlation between CRL or FV and maternal IGFBP-1 or KISS1 levels (p > .05). The maternal IGFBP-1 level during the first trimester was a significant independent factor for SGA and LGA neonates (Odds ratio (OR): 0.011, 95%CI: 1.005-1.018, p < .001; and OR: 1.297, 95%CI: 1.074-1.566, p = .007, respectively). There was no significant relationship between SGA or LGA, and CRL, FV, or the KISS-1 level. As compared to the maternal KISS-1 level, the maternal IGFBP-1 level during the first trimester might be a better biomarker of fetal growth. Additional larger scale studies are needed to further delineate the utility of IGFBP-1 as a marker of abnormal birth weight.
Study Information
pubmed
2018
2018-01-24T00:00:00.000Z
10.1080/14767058.2018.1427720
7
37